RCEL•benzinga•
AVITA Shares Climb Following Positive Results From RECELL System Study In Stable Vitiligo Lesions
Summary
AVITA Medical (NASDAQ: RCEL) reveals positive top-line results from a pivotal trial evaluating the safety and effectiveness of the RECELL System for repigmentation of stable vitiligo lesions.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on September 12, 2022 by benzinga